Q3 Biotech Venture Investing Makes a Boisterous Leap

Life Sciences Tools & DiagnosticsMedical DevicesBiotechnology / Pharmaceuticals

Source: FierceBiotech, John Carroll (10/19/12)

"Using the figures provided by Thomson Reuters, the quarterly report concluded that total life sciences venture deals topped $1.7B in 181 deals in the third quarter—a bit more than a quarter of all investments tracked during the period."

The life sciences industry gained a blast of good news on the venture front today. The National Venture Capital Association and PricewaterhouseCoopers outlined a buoyant set of numbers for the industry, noting a nice spike in the amount invested in biotechs as well as the number of deals completed.

Using the figures provided by Thomson Reuters, the quarterly report concluded that total life sciences venture deals topped $1.7 billion in 181 deals in the third quarter—a bit more than a quarter of all investments tracked during the period. Excluding medical devices, biotech gained $1.2 billion of that for 116 companies, a hefty 64% increase in dollars and a 22% jump in deals. . .View Full Article

AI Collaboration Expands to Accelerate Cancer Drug Discovery
Source: Streetwise Reports (01/12/2026)

Rakovina Therapeutics Inc. (RKV:TSX.V) has broadened its partnership with Variational AI to refine next-generation ATR inhibitors using generative AI. The agreement aims to streamline lead optimization for the company's kt-5000 series of small-molecule cancer drug candidates.

Analysts Highlight Notable H1/26 Catalysts in Biotech
Source: RBC Capital Markets (01/12/2026)

Despite the overall run-up in biotech names last year, the sector still offers "several attractive H1/26 catalyst set-ups, noted an RBC Capital Markets report. Find out which upcoming events the analysts like the most and the least.

Expanded AI Collaboration Advances Optimization of Cancer Drug Candidates
Source: Streetwise Reports (01/09/2026)

Rakovina Therapeutics Inc. (RKV:TSX.V) has expanded its partnership with Variational AI to advance optimization of its kt-5000 ATR inhibitor series. Learn how the agreement deepens the company's use of generative AI to refine small-molecule drug candidates and accelerate preclinical selection.

Clean-Tech Co. Looks Forward to Massive Market Breakthroughs in 2026
Source: Streetwise Reports (12/31/2025)

BioLargo Inc.'s (BLGO:OTCQX) President and Chief Executive Officer Dennis P. Calvert notes the company is looking forward to its part in "what may be one of the largest infrastructure and technology investment cycles in history."

Clean-Tech Firm Anticipates Major Market Advancements in 2026
Source: Streetwise Reports (12/30/2025)

Dennis P. Calvert, President and CEO of BioLargo Inc. (BLGO:OTCQX), mentions that the company is eager to participate in "what may be one of the largest infrastructure and technology investment cycles in history."